Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing

This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from C$1.75 to C$2.00 while reiterating its speculative buy rating after the company closed its C$28.8 million financing. The financing saw the issuing of 27.4 million units, with each unit consisting of one common share and one half warrant at C$1.05 per unit.

Mind Medicine is expected to allocate the proceeds to a number of different initiatives, including:

  • $14.3 million to its four core development programs (18-MC for OUD and LSD for ADHD, anxiety, and cluster headaches)
  • $2.3 million to discovery
  • $3.3 million to general corporate purposes and working capital

Tania Gonsalves, Canaccord’s analyst, says that they are, “taking our R&D estimates up.” As last month during their roadshow, management guided that the 2021 budget is $30-$40 million, which is higher than the $25 million forecasted by Canaccord. She says that knowing the $14.3 million spent on its core programs is in line with its $15.3 million estimate, they are merely adding $10 million to research and development costs for preclinical and discovery work.

Silver47 Exploration Inc. — sponsored Sponsored · Silver47 Exploration Inc.

The main reason for the price target increase is, “MMED’s ending fully diluted share count is lower than anticipated. Together, this has the effect of increasing our target price from $1.75/ sh to C$2.00/sh.” Canaccord prior forecast was under the assumption that Mind Medicine would have had to raise at $0.31 per share versus the $1.05 per unit that they actually managed to conduct the financing at.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

2 Responses

  1. Since Mindmef has applied for uplisting on the Nasdaq can you detail the implications for the IPO price and date? Typically 6 weeks if a longer time which we are now approaching. Thanks so much.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

MindMed Adds MDMA To R&D Pipeline

Mind Medicine, also known as MindMed (NEO: MMED) this morning announced that it is branching...

Wednesday, May 27, 2020, 09:00:04 AM

BMO Lowers Take-Two Interactive’s Price Target By $75 Following Continuous Delays

Last week Take-Two Interactive (NASDAQ: TTWO) announced that they reiterated their 2022 guidance and outlook....

Wednesday, September 29, 2021, 03:48:00 PM

Haywood Initiates Coverage On Cresco Labs With $14.00 Price Target

Last week, Haywood Securities initiated coverage on Cresco Labs (CSE: CL) with a C$14.00 price...

Wednesday, November 4, 2020, 01:59:00 PM

Stifel-GMP: Canopy Growth CEO’s Legacy is “Poor Execution, Misallocated Capital, and Mismanaged Expectations.”

Earlier this month, Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) reported their fiscal second-quarter 2022...

Sunday, November 21, 2021, 12:03:00 PM

First Majestic: BMO Cuts Target To $9.50

Last week First Majestic Silver Corp (TSX: FR) announced its second quarter production results. The...

Thursday, July 28, 2022, 04:46:00 PM